Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a67885d408b1e04a8c966907912fe469 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-75 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-605 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-81 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K19-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-79 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-8107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-53 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-06 |
filingDate |
2005-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77e923e9a49e158eb1e788a6720ba022 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c8e8a8f4cd0b4978bd3a6414a3a71c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8d792700a1c86e891b4a57286affea4c |
publicationDate |
2008-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
MX-2007001424-A |
titleOfInvention |
COMBINATION THERAPY USING TRANSFERRINE FUSION PROTEINS THAT INCLUDE PEPTIDE 1 GLUCAGON TYPE. |
abstract |
The present invention provides a combination therapy comprising transferrin binding protein and DPP-IV inhibitors and / or neutral endopeptidase (NEP) inhibitors. The transferrin fusion protein comprises therapeutic polypeptides or peptides useful in the treatment of diseases such as diabetes. |
priorityDate |
2004-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |